AN EFFECTIVE, ONCE-DAILY CREAM, SAFE FOR LONG-TERM USE?
Skincredible
Plaques illustrated. Not an actual patient.
ZORYVE has been proven effective and safe
In clinical studies, patients with plaque psoriasis using ZORYVE experienced significantly clearer skin.
AFTER 8 WEEKS OF PATIENTS USING ZORYVE:
~40%
Achieved
significantly
clearer skin
~50%
Had clear
or almost
clear skin
ZORYVE was studied in two clinical trials. In the studies, 576 patients were treated with ZORYVE. 305 were treated with a cream not containing the active ingredient. Patients applied ZORYVE once per day to treat mild to severe plaque psoriasis—with affected areas including the elbows, knees, face, intertriginous areas, and genitals. The goal of the clinical trials was achieving clear or almost clear skin at 8 weeks. In a separate safety study, 81 patients were treated with ZORYVE for up to 64 weeks. ZORYVE has not been studied on the scalp, palms, or soles.
AFTER TREATMENT
A TOPICAL THAT HELPS
CLEAR PLAQUES WHERE NEEDED?
Skincredible
Plaques illustrated. Not an actual patient.
*ZORYVE has not been studied on the scalp, palms, or soles.
ZORYVE can be used across body areas
The once-daily topical cream works on areas where skin touches skin—called intertriginous areas (IN-TER-TRIJ-IN-US)
Studies with ZORYVE were the first and only to specifically measure skin clearance in intertriginous areas. Intertriginous areas can include:
ARMPITS | UNDER BREASTS | BETWEEN BUTTOCKS | GROIN | STOMACH FOLDS
AFTER 8 WEEKS of patients using ZORYVE on intertriginous areas:
70%
ACHIEVED
SIGNIFICANTLY
CLEARER SKIN†
†At Week 8, 69 out of 99 patients treated with ZORYVE achieved clearance success in intertriginous areas. See additional study information above.
Did you know?
Plaque psoriasis in intertriginous areas feels and looks different. Skin may appear shiny, smooth, and red and can have significantly less scaling.
Know the difference.
Skin located in intertriginous areas is thinner and may increase absorption of medications, which may increase the risks associated with certain treatments.
Challenging to manage.
More than half of people treating plaque psoriasis in these areas must use more than one topical product, managing each area individually—a challenge to maintain over time.
Skincredible Insight
Being affected by plaque psoriasis in intertriginous areas is very common. Research shows that almost 7 out of 10 people with plaque psoriasis will be affected in intertriginous areas at some point. It's important to share your symptoms—past and present—with your healthcare provider, so they'll be informed to find treatment that's right for you.
AN EFFECTIVE, STEROID-FREE TOPICAL
APPLIED JUST ONCE A DAY?
Skincredible
Plaques illustrated. Not an actual patient.
Patients using ZORYVE reported a reduction IN their plaque psoriasis symptoms scores
In ZORYVE clinical studies, patients answered 16 questions on a 0–10 scale using the PSORIASIS SYMPTOM DIARY (PSD) tool
Every 2 weeks, participants scored the severity and burden of their psoriasis-related symptoms.
Symptoms measured within PSORIASIS SYMPTOM DIARY
ITCH
PAIN
STINGING & BURNING
CRACKING & SCALING
NOTICEABILITY OF PLAQUE COLOR
COVERING UP OF AFFECTED SKIN
ACTIVITY AVOIDANCE WITH OTHER PEOPLE
EMBARRASSMENT
AFTER 8 WEEKS of using ZORYVE, patients recorded a 69% reduction in symptom scores
A decrease in psoriasis-related symptoms and burden was noticed in 2 weeks, which was the first recorded time of measurement.
*Patients recorded psoriasis-related symptom severity and burden on a scale of 0 (none) to 10 (worst) every other week for each symptom for 8 weeks. The percentages show average percent changes in symptom scores. The PSD total score is the sum of 16 questions (0–160).
Talk about treatment options!
The ZORYVE Plaque Psoriasis Conversation Guide can help you prepare for your next healthcare provider visit.
Use The Conversation GuideHow do I apply ZORYVE?
It's easy—find out how once-daily, steroid-free ZORYVE is designed to fit into everyday life.
APPLYING ONCE-DAILY ZORYVE